Strategic partnerships Minerva Imaging has active collaboration activity with Debiopharm Group, Thor Medical and TD2 Oncology, plus a recent channel expansion through a radiopharmaceutical development partnership. This indicates a strong openness to co-development and tech transfer, presenting opportunities to propose joint development programs, access to their radiopharmaceutical capabilities, and cross-sell allied services such as analytical method development and manufacturing support.

US leadership Appointment of a new US General Manager signals a targeted expansion into the United States market. This creates a contact point for selling end-to-end services in North America, including clinical trial support, GMP manufacturing, and regulatory-enabled radiopharmaceutical production through their integrated CRO/CDMO platform.

Alpha and actinium Recent asset acquisition of MH3D’s Alpha-SPECT Mini system and focus on actinium radiopharmaceutical therapy indicate ramping capabilities in alpha therapies. Opportunities exist to position services around radiopharmaceutical development, radiochemistry, imaging, and supply chain readiness for alpha therapies in oncology and related indications.

Global expansion Nordic Capital’s ownership and multiple international partnerships suggest a growth trajectory with an international client base. This supports cross-border service offerings, including translational research, imaging models, and manufacturing capacity scaling to support global clinical programs.

Integrated capabilities As a fully integrated CRO and CDMO with in-house radiopharmaceutical research, development, and manufacturing in Denmark, Minerva Imaging can be positioned as a one-stop partner for clients needing end-to-end radiopharmaceutical programs, from target validation and in vivo imaging to GMP production and regulatory readiness.